Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)
Phase of Trial: Phase I/II
Latest Information Update: 08 Jun 2018
At a glance
- Drugs Letolizumab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 31 Aug 2018 Biomarkers information updated
- 27 Feb 2018 Status changed from active, no longer recruiting to completed.
- 01 Jun 2017 Status changed from recruiting to active, no longer recruiting.